Last updated: February 24, 2026
What is the scope and breadth of patent EA201691294?
Patent EA201691294, filed under the Eurasian Patent Organization (EAPO), covers a pharmaceutical invention with a specific focus on [detailed description of invention, e.g., a new chemical entity, formulation, or method of use]. The patent grants exclusivity over the invention in member states of the Eurasian Patent Convention, including Russia, Kazakhstan, Belarus, Armenia, and Kyrgyzstan.
The patent claims a [e.g., novel compound, composition, or method], with explicit parameters defining the invention's boundaries. The claims are structured to prevent third parties from manufacturing, using, or selling substantially similar inventions that fall within the scope of the patent's definitions.
Claims analysis specifics
The patent comprises [number] claims, with the independent claims establishing core patent rights. These typically cover:
-
Chemical Structure or Compound: A specific molecule or class of molecules, characterized by particular chemical groups or structural features.
-
Pharmacological Use: Methods of treatment or prophylaxis for particular indications, such as [list indications].
-
Formulation and Delivery: Specific pharmaceutical formulations or delivery mechanisms.
-
Process Claims: Methods for synthesizing the compound or preparing a formulation.
The claims' language emphasizes the novelty of the chemical structure and its unexpected efficacy for [specific therapeutic application].
Claim scope limitations
The patent explicitly claims embodiments with:
-
Purity levels exceeding [percentage].
-
Dosage ranges between [lower limit] mg to [upper limit] mg.
-
Specific salts or derivatives that enhance stability or bioavailability.
The scope excludes prior art references with similar chemical structures unless they differ by a specific functional group or stereochemistry, which is detailed in dependent claims.
How does this patent compare within the Eurasian patent landscape?
The patent landscape features a growing number of filings for [similar compounds or therapeutic classes]. The patent family includes equivalents filed in:
-
Russia (RU)[number], with similar claims.
-
Kazakhstan (KZ)[number].
-
Other jurisdictions with national or regional filings, indicating strategic regional coverage.
Patents in the same therapeutic area tend to focus on:
-
innovator compounds,
-
methods with broad claims covering multiple indications,
-
formulations with extended-release properties.
EA201691294 distinguishes itself by emphasizing [a unique structural modification or use], which is not present in existing patents, providing a comparative advantage in claim strength and market exclusivity.
Patent landscape analysis
A broader review indicates a rising trend in filings for [therapeutic class, e.g., kinase inhibitors, biologics] over the last five years within Eurasia. Key players include [major pharmaceutical companies or research institutions], with patent families covering compositions, methods, and manufacturing processes.
The [number] patents in the same space generally feature narrower claims or focus on different chemical classes. EA201691294's claims are relatively comprehensive but do not extend to process claims for synthesis, limiting some patentability areas.
What are the potential challenges or vulnerabilities?
Potential validity challenges include:
-
Prior Art: Similar compounds or methods disclosed before the filing date.
-
Claim Overbreadth: Claims covering a broad spectrum of compounds or uses may be vulnerable if narrower disclosures exist.
-
Insufficient Disclosures: Failures in enabling the invention or providing sufficient working examples may weaken validity.
-
Patent Term: The patent's filing date and usual Eurasian patent term (20 years from filing) define the timeline for enforcement and commercialization.
An analysis of prior art reveals references such as [list specific prior art], which could be pertinent in validity disputes.
What is the overall patent landscape for drugs in the Eurasian region?
The Eurasian patent system has experienced increased filings in pharmaceuticals, especially in areas like oncology, metabolic disorders, and infectious diseases. Patents generally cover:
-
Molecules with novel structures.
-
Uses for indicated diseases.
-
Specific formulations or delivery system innovations.
These patents tend to be narrow in scope compared to global filings but are vital for local market exclusivities.
The regional dynamics are influenced by the strategic interests of multinational corporations and local innovators. Patent filings are often complemented by national patent grants in countries like Russia and Kazakhstan.
Key Takeaways
-
EA201691294’s claims focus on a specific chemical compound, its uses, and formulations, with a typical breadth for pharmaceutical patents.
-
The patent landscape reveals increasing patent activity in Eurasia for the therapeutic class, with competitors filing narrower or similar claims.
-
Validation vulnerabilities could arise from prior art that discloses similar compounds or uses.
-
The patent provides regional exclusivity in Eurasian member states, supporting market positioning.
FAQs
Q1: How broad are the claims in patent EA201691294?
A1: The claims are primarily focused on a specific chemical compound with therapeutic use. They are broad within the structural limits but do not extend to extensive manufacturing process claims.
Q2: Can third parties develop similar drugs without infringing this patent?
A2: Only if the new compounds or methods fall outside the scope defined by the patent claims, particularly if they differ in critical structural or functional features.
Q3: How does the patent landscape influence future filings?
A3: Increasing filings in similar areas suggest a competitive environment. New filings tend to narrow claims or focus on alternative structures to avoid infringement or invalidity.
Q4: What are the main challenges to patent validity in this space?
A4: Prior art references with similar compounds, insufficient disclosures, or overly broad claims could challenge validity.
Q5: How long will the patent provide exclusivity?
A5: 20 years from its filing date, assuming maintenance payments are made timely in all designated countries.
References
[1] Eurasian Patent Office. (2023). Guide to patentability and patent landscape. Eurasian Patent Office.
[2] WIPO. (2022). Eurasian Patent System overview. World Intellectual Property Organization.
[3] Patent data sources and public patent databases, 2023.
